INDICATED FOR THE PALLIATIVE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER, IN WHOM LHRH AGONIST THERAPY IS NOT APPROPRIATE AND WHO REFUSE SURGICAL CASTRATION, AND HAVE ONE OR MORE OF THE FOLLOWING: (1) RISK OF NEUROLOGICAL COMPROMISE DUE TO METASTASES, (2) URETERAL OR BLADDER OUTLET OBSTRUCTION DUE TO LOCAL ENCROACHMENT OR METASTATIC DISEASE, OR (3) SEVERE BONE PAIN FROM SKELETAL METASTASES PERSISTING ON NARCOTIC ANALGESIA.
RECOMMENDED DOSE: 100 MG ADMINISTERED IM TO BUTTOCK ON DAY 1, 15, 29 (WEEK 4) AND EVERY 4 WEEKS THEREAFTER. TREATMENT FAILURE CAN BE DETECTED BY MEASURING SERUM TESTOSTERONE CONCENTRATIONS JUST PRIOR TO INJECTION, BEGINNING ON DAY 29 AND EVERY 8 WEEKS THEREAFTER.
DECREASE IN EFFECTIVENESS WITH CONTINUED DOSING WAS NOTED AS MEASURED BY FAILURE TO MAINTAIN SUPPRESSION OF SERUM TESTOSTERONE BELOW 50 NG/DL AS TREATMENT FAILURE.